Research News and Research

RSS

First edition: September 28, 2009

A look at today's headlines reveals that specific issues regarding the health overhaul effort continue to get significant attention and trigger debate.

28 Sep 2009

Correlagen to use Helicos Genetic Analysis System for diagnosing genetic disorders

Correlagen Diagnostics Inc., a leading provider of genetic testing for disease diagnosis, today announced the acquisition of a system from and a scientific collaboration with Helicos BioSciences Corporation.

28 Sep 2009

New Fragment Screening Platform from Selcia

Selcia Ltd, a worldwide industry leading C-14 custom radiolabelling provider and drug discovery company this week launched their new Fragment Screening Platform and unveiled their new brand as part of ambitious international expansion plans.

28 Sep 2009

New scalable solutions for targeted re-sequencing studies from febit holding and Life Technologies

febit holding GmbH and Life Technologies Corporation today announced that they have entered into a strategic co-marketing agreement to provide a new, scalable solution for researchers conducting targeted re-sequencing studies. In addition, febit will expand its Genomic Services Facility at Heidelberg by adding several Applied Biosystems SOLiD™ high-throughput sequencing systems and real-time PCR systems.

28 Sep 2009

Illumina to defend Genome Analyzer System patent infringement suit

Illumina, Inc. today announced that it has been served with a complaint filed on September 21, 2009 in the U.S. District Court in Wilmington, Delaware naming Illumina as a defendant. The complaint names as plaintiffs Life Technologies Corporation; Applied Biosystems LLC; a Russian research institute; two individuals listed as inventors on the asserted patents; and another individual who appears to have an ownership interest in the patents.

From Illumina, Inc. 28 Sep 2009

Covidien to acquire Aspect Medical Systems

Covidien (NYSE: COV) and Aspect Medical Systems, Inc. (NASDAQ: ASPM) today announced that Covidien has reached a definitive agreement to acquire Aspect, a global market leader in brain monitoring technology.

28 Sep 2009

JEBDP editors to offer continuing education units for its reviewers

Elsevier, a leading publisher of scientific, technical and medical information products and services announced today, that the Editors of Journal of Evidence-Based Dental Practice (JEBDP), the foremost publication of information about evidence-based dental practice, will begin offering continuing education units (CEUs) to its recognized experts and valued peer reviewers.

28 Sep 2009

Study on how epigenetic changes contribute to congnitive decline

The National Institutes of Health has awarded Rush University Medical Center approximately $5.5 million in grants to study how epigenetic changes - chemical modifications to genes that result from diet, aging, stress, or environmental exposures - define and contribute to memory formation and cognitive decline. Results from the studies could profoundly alter the way the medical community understands, diagnoses, and treats Alzheimer's disease, according to the researchers.

28 Sep 2009

MedPro and Advanced MedTech to develop new passive needlestick injury prevention technologies

MedPro Safety Products, Inc. (OTCBB: MPSP), a pioneer in the development and marketing of passive needlestick injury prevention technology, entered into an exclusive agreement with Advanced MedTech (AMT). AMT is wholly owned by Hooman Asbgahi, the inventor of MedPro’s phlebotomy products, marketed by Greiner Bio-One GmbH under its VACUETTE® brand as the VACUETTE® PREMIUM Safety Needle System and VACUETTE® PREMIUM Blood Collection Set.

28 Sep 2009

Thommen Medical launches two implant conditioning systems

Thommen Medical, a leading Swiss company in the area of the oral implantology, will officially launch the latest products in the evolution of implant surface technology, APLIQUIQ and INICELL, at the 2009 AAOMS Meeting in Toronto, Canada.

28 Sep 2009

Safety profiles of JANUVIA and JANUMET drugs established through clinical development program

Merck has thoroughly reviewed the safety data for sitagliptin, and sitagliptin was not associated with an increase in the incidence of pancreatitis in preclinical studies or in clinical trials of up to two years in duration with more than 6,000 patients.

28 Sep 2009

Plant gene regulating oil accumulation in plant seed licensed to BASF Plant Science

Technology that could enhance plants' seed oil content for food and animal feed applications has been licensed to BASF Plant Science under an exclusive commercial agreement with Michigan State University.

28 Sep 2009

UK scientists discover new route by which leukaemia develops

CANCER RESEARCH UK SCIENTISTS have discovered a completely new route by which leukaemia develops, according to research published in Nature.

28 Sep 2009

Combined immunodeficiency results in severe health problems

Researchers at the National Institutes of Health have identified a genetic mutation that accounts for a perplexing condition found in people with an inherited immunodeficiency. The disorder, called combined immunodeficiency, is characterized by a constellation of severe health problems, including persistent bacterial and viral skin infections, severe eczema, acute allergies and asthma, and cancer.

28 Sep 2009

An overview on nanoparticles

At SINTEF scientist both exploit the benefits of the nanotechnology and try to discover how tiny particles could behave hazardous in nature.

28 Sep 2009

Merck, Qiagen pledge cervical cancer tools at CGI, meeting highlights effects of gender inequality

Drugmaker Merck & Co. announced Wednesday at the Clinton Global Initiative's (CGI) annual meeting in New York that it will "donate more than $500 million of its Gardasil cervical cancer vaccine" with the goal of improving women's health in developing countries, Bloomberg reports.

From QIAGEN Manchester Limited 28 Sep 2009

$1.3 million fund awarded to WPI for ongoing life sciences research

Researchers at Worcester Polytechnic Institute's (WPI) Life Sciences and Bioengineering Center at Gateway Park have received a total of $1.3 million in new awards from the National Institutes of Health (NIH) and the National Science Foundation (NSF) to fund ongoing research in several areas of the life sciences, including a study of the bacterium that causes tuberculosis, work aimed at using adult stem cells to repair damaged hearts, and a project that seeks to create engineered blood vessels.

28 Sep 2009

Study links diabetes to atrial fibrillation in women

Diabetes increases by 26 percent the likelihood that women will develop atrial fibrillation (AF), a potentially dangerous irregular heart rhythm that can lead to stroke, heart failure, and chronic fatigue. These are the findings of a new Kaiser Permanente study, published in the October issue of Diabetes Care, a journal of the American Diabetes Association.

28 Sep 2009

Misregulation of SPAK protein may contribute to B-cell lymphoma development

A group led by Dr. Michael Teitell at UCLA has demonstrated that misregulation of the protein SPAK may contribute to B-cell lymphoma development. Their report can be found in the October 2009 issue of the American Journal of Pathology.

28 Sep 2009

U.S. underfunds climate change health-related research

A recent commentary suggests that the U.S. should spend roughly $197 million more than it currently does to research the impact of climate change on public health.

28 Sep 2009